[The dopaminergic hypothesis revisited].
Guillin
O
O
Centre Paul Broca, Unité 573, 2 ter, rue d'Alésia, 75014 Paris.
D014150:Antipsychotic Agents / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D003072:Cognition Disorders / Q000188:drug therapy / Q000503:physiopathology; D004298:Dopamine / Q000502:physiology*; D018492:Dopamine Antagonists / Q000627:therapeutic use; D006801:Humans; D049268:Positron-Emission Tomography; D011569:Psychiatric Status Rating Scales; D017447:Receptors, Dopamine D1 / Q000187:drug effects / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000502:physiology; D050637:Receptors, Dopamine D3 / Q000187:drug effects / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology*; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D004298:Dopamine